DK3129018T3 - Behandling af NAFLD og NASH - Google Patents

Behandling af NAFLD og NASH Download PDF

Info

Publication number: DK3129018T3
Authority: DK; Denmark
Prior art keywords: nafld; nash; treatment
Prior art date: 2014-04-11

Application number

DK15728222.9T

Other languages

English (en)

Inventor

Brian Roberts

Xueyan Wang

Yun-Jung Choi

David Karpf

Robert Martin

Charles A Mcwherter

Original Assignee

Cymabay Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-11

Filing date

2015-04-10

Publication date

2020-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3129018(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-10 Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc

2020-01-20 Application granted granted Critical

2020-01-20 Publication of DK3129018T3 publication Critical patent/DK3129018T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Separation Using Semi-Permeable Membranes (AREA)

DK15728222.9T 2014-04-11 2015-04-10 Behandling af NAFLD og NASH DK3129018T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461978335P	2014-04-11	2014-04-11
PCT/US2015/025416 WO2015157697A1 (en)	2014-04-11	2015-04-10	Treatment of nafld and nash

Publications (1)

Publication Number	Publication Date
DK3129018T3 true DK3129018T3 (da)	2020-01-20

Family

ID=53373532

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15728222.9T DK3129018T3 (da)	2014-04-11	2015-04-10	Behandling af NAFLD og NASH

Country Status (27)

Country	Link
US (7)	US9381181B2 (da)
EP (1)	EP3129018B1 (da)
JP (1)	JP6865038B2 (da)
KR (1)	KR102374499B1 (da)
CN (1)	CN106163508A (da)
AU (1)	AU2015243239B2 (da)
BR (1)	BR112016023269A8 (da)
CA (1)	CA2944139C (da)
CL (1)	CL2016002517A1 (da)
CY (1)	CY1122602T1 (da)
DK (1)	DK3129018T3 (da)
EA (1)	EA036704B1 (da)
ES (1)	ES2764467T3 (da)
HR (1)	HRP20192299T1 (da)
IL (1)	IL248193B (da)
LT (1)	LT3129018T (da)
MX (1)	MX369921B (da)
NZ (1)	NZ724740A (da)
PH (1)	PH12016501978B1 (da)
PL (1)	PL3129018T3 (da)
PT (1)	PT3129018T (da)
RS (1)	RS59637B1 (da)
SG (1)	SG11201608077PA (da)
SI (1)	SI3129018T1 (da)
SM (1)	SMT202000019T1 (da)
UA (1)	UA121208C2 (da)
WO (1)	WO2015157697A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010028067A1 (en)	2008-09-02	2010-03-11	Amarin Corporation Plc	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
CA2740874C (en) *	2008-10-17	2018-02-27	Metabolex, Inc.	Use of ppar.gamma.agonists to reduce small dense ldl particles
SG175390A1 (en)	2009-04-29	2011-12-29	Amarin Corp Plc	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2010241571B2 (en)	2009-04-29	2014-06-26	Amarin Pharmaceuticals Ireland Limited	Stable pharmaceutical composition and methods of using same
PL3318255T3 (pl)	2009-06-15	2021-09-06	Amarin Pharmaceuticals Ireland Limited	Kompozycje i sposoby leczenia udaru u pacjenta z jednoczesną terapią statyną
CA2775339C (en)	2009-09-23	2017-03-28	Amarin Corporation Plc	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US9719068B2 (en)	2010-05-06	2017-08-01	Children's Hospital Medical Center	Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en)	2010-11-29	2014-03-26	Amarin Pharma Inc	COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
WO2013070735A1 (en)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US9827219B2 (en)	2012-01-06	2017-11-28	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
IL275396B2 (en)	2012-06-29	2024-11-01	Amarin Pharmaceuticals Ie Ltd	Eicosapentaenoic acid and docosapentaenoic acid for use as a medicament for reducing a risk of cardiovascular death
US20150265566A1 (en)	2012-11-06	2015-09-24	Amarin Pharmaceuticals Ireland Limited	Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) *	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
BR112016020260A8 (pt)	2014-03-20	2021-06-29	Cymabay Therapeutics Inc	uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
US10272058B2 (en)	2014-03-20	2019-04-30	Cymabay Therapeutics, Inc.	Treatment of intrahepatic cholestatic diseases
EP3129018B1 (en)	2014-04-11	2019-10-23	CymaBay Therapeutics, Inc.	Treatment of nafld and nash
CN113249297A (zh)	2014-05-28	2021-08-13	儿童医院医疗中心	用于经由定向分化将前体细胞转化为胃组织的方法和系统
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CA2963704A1 (en)	2014-10-17	2016-04-21	Children's Hospital Medical Center	In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
WO2016154258A1 (en) *	2015-03-26	2016-09-29	T3D Therapeutics, Inc.	Methods of treating liver disease using indane acetic acid derivatives
CA2983377C (en)	2015-04-28	2023-08-29	Pronova Biopharma Norge As	Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
WO2017049157A1 (en) *	2015-09-18	2017-03-23	Duke University	Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en)	2016-02-10	2017-08-17	Synlogic, Inc.	Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en)	2016-03-31	2024-08-06	Genfit	Methods of treatment of cholestatic diseases
EP4177335A1 (en)	2016-05-05	2023-05-10	Children's Hospital Medical Center	Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en)	2016-08-24	2016-10-05	Univ Oxford Innovation Ltd	Biomarkers
US10668108B2 (en)	2016-11-04	2020-06-02	Children's Hospital Medical Center	Compositions and methods of treating liver disease
US10493363B2 (en) *	2016-11-09	2019-12-03	Activision Publishing, Inc.	Reality-based video game elements
KR20230110839A (ko)	2016-12-05	2023-07-25	칠드런즈 호스피탈 메디칼 센터	결장 유사장기 및 이를 제조 및 사용하는 방법
EP3619193B1 (en)	2017-05-05	2023-03-22	Hepanova, Inc.	Amino-aryl-benzamide compounds and methods of use thereof
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10512622B2 (en)	2017-07-14	2019-12-24	Cymabay Therapeutics, Inc.	Treatment of intrahepatic cholestatic diseases
JP2020533339A (ja)	2017-09-13	2020-11-19	ノバルティスアーゲー	Ｆｘｒアゴニストを含む組合せ
JP6976030B2 (ja)	2017-10-27	2021-12-01	サムヤンコーポレイション	非アルコール性脂肪肝疾患の予防または改善用組成物
SG11202005007VA (en)	2017-12-06	2020-06-29	Basf As	Fatty acid derivatives for treating non-alcoholic steatohepatitis
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
AU2019349563B2 (en)	2018-09-24	2023-06-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of cardiovascular events in a subject
JP2022507644A (ja) *	2018-11-16	2022-01-18	サイマベイ・セラピューティクス・インコーポレイテッド	Ｎａｆｌｄおよびｎａｓｈの併用治療
EP3880187A1 (en)	2018-11-16	2021-09-22	CymaBay Therapeutics, Inc.	Treatment of obesity and its complications
WO2021097027A1 (en) *	2019-11-14	2021-05-20	Cymabay Therapeutics, Inc.	Seladelpar for use in the treatment of alcoholic liver disease
WO2021097034A1 (en) *	2019-11-14	2021-05-20	Cymabay Therapeutics, Inc.	Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
AU2021273487A1 (en) *	2020-05-13	2023-01-05	Terns Pharmaceuticals, Inc.	Combination treatment of liver disorders
AU2022263358A1 (en)	2021-04-21	2023-11-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure
CA3214214A1 (en) *	2021-05-11	2022-11-17	Genfit	Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7101993B1 (en)	1990-01-11	2006-09-05	Isis Pharmaceuticals, Inc.	Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en)	1995-03-06	2001-04-24	Isis Pharmaceuticals, Inc.	Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JP4293636B2 (ja)	1996-02-14	2009-07-08	アイシス・ファーマシューティカルス・インコーポレーテッド	糖修飾ギャップ付オリゴヌクレオチド
US5883109A (en)	1996-07-24	1999-03-16	Bristol-Myers Squibb Company	Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en)	1997-01-17	2000-05-23	Bristol-Myers Squibb Co.	Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
CA2539446C (en)	2003-09-19	2013-12-03	Janssen Pharmaceutica, N.V.	4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
SI1725234T1 (sl)	2004-03-05	2013-04-30	The Trustees Of The University Of Pennsylvania	Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
JO3006B1 (ar) *	2005-09-14	2016-09-05	Janssen Pharmaceutica Nv	املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US20080176861A1 (en)	2007-01-23	2008-07-24	Kalypsys, Inc.	Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
CA2740874C (en)	2008-10-17	2018-02-27	Metabolex, Inc.	Use of ppar.gamma.agonists to reduce small dense ldl particles
JOP20200043A1 (ar)	2011-05-10	2017-06-16	Amgen Inc	طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2014353246A1 (en)	2013-11-20	2016-06-16	Cymabay Therapeutics, Inc.	Treatment of homozygous familial hypercholesterolemia
BR112016020260A8 (pt)	2014-03-20	2021-06-29	Cymabay Therapeutics Inc	uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
EP3129018B1 (en) *	2014-04-11	2019-10-23	CymaBay Therapeutics, Inc.	Treatment of nafld and nash
WO2015200580A1 (en)	2014-06-26	2015-12-30	Cymabay Therapeutics, Inc.	Treatment of severe hypertriglyceridemia

2015
- 2015-04-10 EP EP15728222.9A patent/EP3129018B1/en active Active
- 2015-04-10 LT LTEP15728222.9T patent/LT3129018T/lt unknown
- 2015-04-10 SM SM20200019T patent/SMT202000019T1/it unknown
- 2015-04-10 EA EA201692050A patent/EA036704B1/ru unknown
- 2015-04-10 SG SG11201608077PA patent/SG11201608077PA/en unknown
- 2015-04-10 PL PL15728222T patent/PL3129018T3/pl unknown
- 2015-04-10 WO PCT/US2015/025416 patent/WO2015157697A1/en active Application Filing
- 2015-04-10 SI SI201531047T patent/SI3129018T1/sl unknown
- 2015-04-10 US US14/684,100 patent/US9381181B2/en active Active
- 2015-04-10 UA UAA201609927A patent/UA121208C2/uk unknown
- 2015-04-10 CN CN201580018550.9A patent/CN106163508A/zh active Pending
- 2015-04-10 PH PH1/2016/501978A patent/PH12016501978B1/en unknown
- 2015-04-10 JP JP2016561799A patent/JP6865038B2/ja active Active
- 2015-04-10 RS RS20191583A patent/RS59637B1/sr unknown
- 2015-04-10 BR BR112016023269A patent/BR112016023269A8/pt not_active Application Discontinuation
- 2015-04-10 PT PT157282229T patent/PT3129018T/pt unknown
- 2015-04-10 CA CA2944139A patent/CA2944139C/en active Active
- 2015-04-10 ES ES15728222T patent/ES2764467T3/es active Active
- 2015-04-10 AU AU2015243239A patent/AU2015243239B2/en active Active
- 2015-04-10 NZ NZ72474015A patent/NZ724740A/en unknown
- 2015-04-10 KR KR1020167031356A patent/KR102374499B1/ko active Active
- 2015-04-10 DK DK15728222.9T patent/DK3129018T3/da active
- 2015-04-10 MX MX2016013375A patent/MX369921B/es active IP Right Grant
2016
- 2016-06-02 US US15/171,910 patent/US9616039B2/en active Active
- 2016-10-04 CL CL2016002517A patent/CL2016002517A1/es unknown
- 2016-10-05 IL IL248193A patent/IL248193B/en active IP Right Grant
2017
- 2017-03-02 US US15/447,895 patent/US9962346B2/en active Active
2018
- 2018-04-03 US US15/943,936 patent/US10188620B2/en active Active
- 2018-12-17 US US16/222,379 patent/US10342770B2/en active Active
2019
- 2019-05-23 US US16/420,465 patent/US10722483B2/en active Active
- 2019-12-20 CY CY20191101347T patent/CY1122602T1/el unknown
- 2019-12-20 HR HRP20192299TT patent/HRP20192299T1/hr unknown
2020
- 2020-06-19 US US16/906,296 patent/US11179359B2/en active Active

Also Published As

Publication number	Publication date
US20200009092A1 (en)	2020-01-09
PH12016501978B1 (en)	2023-07-12
WO2015157697A1 (en)	2015-10-15
US20190142776A1 (en)	2019-05-16
US20210038546A1 (en)	2021-02-11
EP3129018A1 (en)	2017-02-15
EP3129018B1 (en)	2019-10-23
RS59637B1 (sr)	2020-01-31
CY1122602T1 (el)	2021-03-12
US10188620B2 (en)	2019-01-29
JP2017513836A (ja)	2017-06-01
US11179359B2 (en)	2021-11-23
MX2016013375A (es)	2017-02-15
UA121208C2 (uk)	2020-04-27
BR112016023269A8 (pt)	2021-06-29
CA2944139A1 (en)	2015-10-15
PH12016501978A1 (en)	2016-12-19
US9962346B2 (en)	2018-05-08
EA036704B1 (ru)	2020-12-10
JP6865038B2 (ja)	2021-04-28
PT3129018T (pt)	2020-01-15
US9381181B2 (en)	2016-07-05
KR102374499B1 (ko)	2022-03-14
US20180228752A1 (en)	2018-08-16
KR20160136451A (ko)	2016-11-29
US20160324812A1 (en)	2016-11-10
AU2015243239B2 (en)	2019-11-14
CL2016002517A1 (es)	2017-05-05
PL3129018T3 (pl)	2020-05-18
US10342770B2 (en)	2019-07-09
LT3129018T (lt)	2020-01-10
US10722483B2 (en)	2020-07-28
US9616039B2 (en)	2017-04-11
SMT202000019T1 (it)	2020-03-13
SG11201608077PA (en)	2016-10-28
MX369921B (es)	2019-11-26
AU2015243239A1 (en)	2016-10-20
US20180008566A1 (en)	2018-01-11
US20150290154A1 (en)	2015-10-15
CA2944139C (en)	2020-11-03
NZ724740A (en)	2019-11-29
IL248193B (en)	2019-03-31
SI3129018T1 (sl)	2020-02-28
HRP20192299T1 (hr)	2020-03-06
EA201692050A1 (ru)	2017-01-30
ES2764467T3 (es)	2020-06-03
CN106163508A (zh)	2016-11-23
BR112016023269A2 (pt)	2017-08-15

Publication	Publication Date	Title
DK3129018T3 (da)	2020-01-20	Behandling af NAFLD og NASH
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3851537T5 (da)	2024-08-19	Behandling af hyperbilirubinæmi
DK3234133T3 (da)	2021-02-08	Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
IL252026B (en)	2021-10-31	Humanized anti-complement factor c1q antibodies and uses thereof
DK3259597T3 (da)	2022-05-09	Pvrig-polypeptider og fremgangsmåder til behandling
DK3155024T3 (da)	2020-11-23	Opholdsstrukturer og relaterede fremgangsmåder
DK2949365T3 (da)	2020-10-19	Gåtræningsapparat og gåtræningsfremgangsmåde deraf
DK3218358T3 (da)	2021-08-30	Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3018183T3 (da)	2022-12-05	Halogenolefinbaseret sammensætning og anvendelse deraf
DK3102200T3 (da)	2023-05-22	Terapeutisk forbindelse og sammensætning
DK2964255T3 (da)	2021-02-08	Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
DK3209696T3 (da)	2021-08-09	Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3142664T3 (da)	2020-03-09	Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3194564T3 (da)	2020-10-19	Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3089971T3 (da)	2020-08-31	Forbindelser og fremgangsmåder til anvendelse
DK3242947T3 (da)	2020-08-03	Genterapi og elektroporese til behandling af maligniteter
DK3161139T3 (da)	2020-10-19	Tlr-4-specifikke aptamerer og anvendelser heraf
DK3265641T3 (da)	2020-03-16	Stigørenhed og fremgangsmåde
DK3110446T3 (da)	2022-02-28	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3237621T3 (da)	2023-06-19	Varianter af human alpha-galactosidase
DK3265126T3 (da)	2021-09-13	Kombinationsformulering af tesofensin og metoprolol
DK3191103T3 (da)	2021-09-27	Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
DK3183201T3 (da)	2021-06-14	Spilsamling og fremgangsmåde til anvendelse
DK3194583T3 (da)	2021-12-20	Ikke-fucosyleret protein og fremgangsmåder dermed